Semax and Selank occupy a curious position in the neuropeptide landscape: both are derived from ACTH, both emerged from Russian clinical research, and both have generated substantial interest in the neuroscience community. Yet their molecular mechanisms diverge sharply, targeting distinct neurotransmitter systems and triggering different downstream cascades in rodent models. For researchers designing in vitro assays, ex vivo tissue preparations, or behavioural studies, conflating these peptides risks confounded results and wasted resources.
This article compares the two compounds head-to-head, examining what published research reveals about their structural origins, their principal neurotransmitter targets, and the evidence for their contrasting nootropic pathways. Whether you are selecting a peptide for a memory-enhancement protocol or an anxiety-reduction study, understanding these mechanistic distinctions is critical to rigorous experimental design.
Key takeaways
- Semax (ACTH(4-10) analogue) induces BDNF and TrkB expression via PACAP-cAMP-CREB signalling in hippocampal neurons, with timescale of hours to days; Selank (tetrapeptide) modulates GABA and serotonin systems at the receptor level within minutes to hours.
- Semax's mechanism prioritises synaptic plasticity and learning enhancement; Selank's mechanism prioritises anxiolysis and network stabilisation—these are not competing descriptions of the same pathway but distinct pharmacologies.
- No head-to-head controlled comparison of Semax and Selank using identical assays in the same animal cohort has been published; such studies would help clarify potential additive or synergistic effects.
- Preclinical evidence for both peptides is robust in rodent models but does not yet extend to human clinical trials in the EU, US, or most other jurisdictions; both remain research compounds only.
- High-purity, lot-specific certificates of analysis with HPLC and mass spectrometry are critical quality markers when sourcing either peptide; King Peptides provides 98% or higher HPLC purity with full documentation and rapid EU dispatch.
Structural Origins: Shared ACTH Heritage, Distinct Sequence Architecture
Both Semax and Selank descend from the adrenocorticotropic hormone (ACTH), one of the body's most ancient stress-response peptides. However, they represent different strategies for harnessing ACTH's non-hormonal properties.
Semax is a seven-amino-acid ACTH(4-10) analogue with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Crucially, it retains only the central fragment of ACTH while shedding the N-terminal residues responsible for activating corticotropin receptors. This modification eliminates the hormonal side effects that limit full-length ACTH's utility in research and clinical settings, whilst preserving the neuropeptide's capacity to influence neurotrophin expression.
Selank, by contrast, is a tetrapeptide—Thr-Asp-Pro-Gly—derived from a different region of the ACTH molecule. Its smaller size and distinct sequence confer properties unrelated to ACTH's corticotropic function. Selank has never shown hormonal activity in experimental models, yet it achieves potent anxiolytic and nootropic effects through mechanisms that remain partially dissociated from Semax's primary pathways.
Semax: BDNF Induction Through PACAP Signalling
The most extensively documented action of Semax in rodent models centres on brain-derived neurotrophic factor (BDNF) elevation in the hippocampus. Research has demonstrated that a single intranasal or systemic dose of Semax produces a rapid increase in BDNF messenger RNA and protein expression, accompanied by upregulation of tropomyosin-related kinase B (TrkB), the primary receptor through which BDNF exerts its effects on neuronal survival, growth, and long-term potentiation.
This effect appears to be mediated through pituitary adenylyl cyclase-activating peptide (PACAP) signalling and downstream activation of adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP in turn activates the cyclic AMP response element binding (CREB) transcription factor, which directly promotes BDNF gene transcription in hippocampal neurons. This pathway is distinct from classical monoamine neurotransmission; it operates at the level of gene expression and cellular differentiation.
The functional consequence of Semax-induced BDNF elevation in animals includes enhanced learning capacity, improved memory consolidation, and neuroprotection against excitotoxic stress. These effects have been observed in multiple rodent models, though all evidence remains preclinical.
Selank: GABA and Serotonin Modulation via Distinct Receptors
Selank's nootropic and anxiolytic actions rely on fundamentally different neurotransmitter systems. The tetrapeptide has been shown to enhance GABAergic neurotransmission, the brain's primary inhibitory system, by mechanisms that may involve allosteric modulation of GABA-A receptors or upregulation of GABAergic interneuron activity. This direct action on inhibitory tone explains Selank's prominent anxiolytic profile in rodent models of conditioned fear and elevated-plus-maze testing.
Additionally, Selank appears to modulate serotonergic systems, with some research indicating effects on serotonin transporter expression and reuptake kinetics. This dual action on GABA and serotonin contrasts sharply with Semax's focus on neurotrophic signalling. Whilst Semax works by encoding growth and plasticity signals, Selank achieves its anxiolytic and mood-stabilising effects by adjusting the balance of inhibitory and monoaminergic neurotransmission in real time.
Comparing Mechanisms: Timescale, Target Cells, and Functional Outcomes
A direct mechanism comparison reveals why these peptides are not interchangeable in research protocols:
| Parameter | Semax | Selank |
|---|---|---|
| Primary mechanism | BDNF induction via PACAP and cAMP–CREB signalling | GABA and serotonin receptor modulation |
| Timescale of action | Gene transcription and protein synthesis (hours to days) | Receptor-level neurotransmission (minutes to hours) |
| Target cell types | Pyramidal neurons and glutamatergic circuits | GABAergic interneurons and serotonergic neurons |
| Hippocampal outcome | Enhanced synaptic plasticity and LTP | Anxiety reduction and network stabilisation |
| Neuroendocrine sequelae | None (no HPA axis activation) | None (no cortisol or ACTH elevation) |
These distinctions have profound implications for experimental design. A researcher investigating learning and memory consolidation should prioritise Semax's neurotrophic actions; one examining anxiety-related behaviours or stress resilience would be better served by Selank's GABAergic and serotonergic effects. Co-administration might yield additive or synergistic outcomes—a question that remains largely unexplored in the literature—but should not be undertaken without clear mechanistic prediction and appropriate controls.
Preclinical Evidence: What Rodent Models Have Revealed
Semax has been characterised most extensively in hippocampal slice preparations and in vivo dosing studies. A landmark observation reported that a single dose produced fast increases in BDNF and TrkB expression in the rat hippocampus, measured within hours. Behavioural studies have supported enhancement of spatial learning and memory retention in water maze and radial arm maze tasks.
Selank research has centred on anxiety-related phenotypes, with robust data showing reduced freezing in fear-conditioning paradigms and increased open-arm exploration in elevated-plus-maze tests—standard markers of GABAergic disinhibition. Some studies report mild pro-cognitive effects in object recognition and passive avoidance tasks, though the primary pharmacological action clearly targets anxiolysis rather than memory encoding per se.
Critically, no published studies have directly compared Semax and Selank within the same experimental protocol using identical assays, controls, and dosing schedules. Such a comparison would be a valuable contribution to the neuropeptide literature but remains absent to date.
Practical Considerations for in Vitro and Ex Vivo Experimental Design
When sourcing research-grade Semax or Selank, rigorous quality control is non-negotiable. Semax 5 mg from King Peptides comes supplied with a lot-specific certificate of analysis detailing HPLC purity of 98% or higher (99% or higher for most products, as listed on their lab reports page) and mass spectrometry confirmation of amino acid sequence. Dispatch from the Netherlands in a tracked parcel ensures arrival within 1–2 business days in the Netherlands or 3–5 business days to Belgium and Luxembourg, with no customs procedures inside the EU.
For hippocampal slice experiments using Semax, bath application at concentrations in the nanomolar to low-micromolar range is typical in published protocols, with measurement of BDNF protein and mRNA as primary endpoints. Electrophysiological recording of field excitatory postsynaptic potentials (fEPSPs) or whole-cell currents provides functional validation of PACAP and cAMP signalling engagement.
Selank studies often employ acute or chronic systemic dosing (intranasal or intraperitoneal administration in rodents) prior to behavioural or neurochemical assay, with plasma and brain tissue sampling for GABA, serotonin, and serotonin metabolite quantification. Receptor binding assays using radioligand or fluorescent ligands can confirm target engagement at GABA-A and serotonin transporters.
When to Use Each Peptide: Experimental Design Recommendations
The choice between Semax and Selank should flow directly from your research question:
- Choose Semax if your primary interest is memory formation, synaptic plasticity, neuroprotection against excitotoxic or ischaemic insult, or BDNF-dependent cellular processes in cortical or hippocampal circuits.
- Choose Selank if you are investigating anxiolytic mechanisms, stress resilience, acute or chronic fear-related behaviours, or serotonergic and GABAergic circuit function.
- Consider both if you hypothesise that reduced anxiety (via Selank) could secondarily enhance learning (via Semax), or if you wish to examine interaction effects—but design such experiments with appropriate washout periods and randomised treatment order to avoid confounding.
All evidence for both peptides remains preclinical. Neither has been approved by the European Medicines Agency for human use. Semax is registered in Russia as intranasal drops, but this registration reflects local regulatory pathways and does not constitute approval in the EU, the United States, or most other jurisdictions. Research use only.
Conclusion
Semax and Selank are not interchangeable neuropeptides, despite their shared ACTH origin and Russian clinical heritage. Semax operates as a neurotrophic agent, driving BDNF expression and synaptic plasticity through PACAP-dependent signalling; Selank functions as an anxiolytic and mood-stabiliser by modulating GABA and serotonin systems at the receptor and transporter level. Understanding these distinct mechanisms is essential for rigorous experimental design, appropriate control selection, and honest interpretation of results. For researchers in the Netherlands, Belgium, and Luxembourg, sourcing high-purity, quality-assured peptides from King Peptides ensures that mechanistic conclusions rest on validated compounds rather than degraded or mislabelled material. Always consult published protocols specific to your chosen peptide, and maintain clear separation of preclinical and clinical claims.
Frequently asked questions
Is Semax the same as Selank?
No. Although both derive from ACTH and emerged from Russian research, they differ fundamentally in structure (Semax is a seven-amino-acid ACTH fragment; Selank is a four-amino-acid tetrapeptide) and mechanism (Semax drives BDNF via PACAP signalling; Selank modulates GABA and serotonin). Confusing them in experimental design would yield confounded results.
Can I use Semax for anxiety reduction?
Semax's primary mechanism—BDNF-driven neuroplasticity—does produce some anxiolytic effects as a secondary consequence of enhanced circuit adaptability. However, Selank's direct GABAergic action makes it the more appropriate choice for acute or targeted anxiety studies. Semax is better suited to memory and neuroprotection protocols.
What is the timescale of action for Semax versus Selank?
Semax operates via gene transcription and protein synthesis, with measurable BDNF elevation within hours and behavioural changes evident over days. Selank acts at the neurotransmitter receptor level, with rapid onset within minutes to hours. This difference is crucial for study design: Semax requires sustained dosing or measurement windows; Selank may show acute effects after single administration.
Do I need special storage conditions for these peptides?
Both Semax and Selank are lyophilised peptides supplied by King Peptides with full reconstitution and storage guidance. Standard protocols recommend storage at −20 °C or below prior to reconstitution, and refrigeration (2–8 °C) of reconstituted solutions. Refer to the lot-specific certificate of analysis and the supplier's bench protocol for details specific to your purchase.
Is there evidence these peptides work in humans?
Semax is registered in Russia as intranasal drops for post-stroke recovery, but this does not constitute European Medicines Agency approval or robust clinical evidence in EU-resident populations. All mechanistic and efficacy data cited in this article derive from preclinical rodent models. Neither peptide is approved for human use in the EU, and all research remains investigational.
Research use only. This article summarises published research for laboratory purposes and is not medical advice. Research material has no marketing authorisation and is not meant for human or veterinary use, whatever the status of the molecule as a medicine. Written by the PeptidenBenelux.com research desk with AI assistance; check every claim against the primary literature.